# US 2004/0082002 A1 · 37 staphylococcus aureus genes and polypeptides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0082002 A1
- Document ID: US20040082002A1
- Status: Published application
- Kind: A1
- Application number: 10/712,713
- Filed: 2003-11-14
- Published: 2004-04-29
- Earliest claimed: 1999-09-01
- Inventors: Gil H. Choi
- Web page: https://patentgrep.com/patent/US20040082002A1

## CPC

- C07K 14/31: from Staphylococcus (G)
- A61P 31/04: Antibacterial agents
- C12Q 1/689: for bacteria
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to novel genes from S. aureus and the polypeptides they encode. Also provided as are vectors, host cells, antibodies and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of S. aureus polypeptide activity. The invention additionally relates to diagnostic methods for detecting Staphylococcus nucleic acids, polypeptides and antibodies in a biological sample. The present invention further relates to novel vaccines for the prevention or attenuation of infection by Staphylococcus.

## Claims

### Claim 1

An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence selected from the group consisting of:
(a) a nucleotide sequence encoding any one of the amino acid sequences of the polypeptides shown in Table 1; or
(b) a nucleotide sequence complementary to any one of the nucleotide sequences in
(a).
(c) a nucleotide sequence at least 95% identical to any one of the nucleotide sequences shown in Table 1; or,
(d) a nucleotide sequence at least 95% identical to a nucleotide sequence complementary to any one of the nucleotide sequences shown in Table 1.

### Claim 2 (depends on 1)

An isolated nucleic acid molecule of claim 1 comprising a polynucleotide which hybridizes under stringent hybridization conditions to a polynucleotide having a nucleotide sequence identical to a nucleotide sequence in (a) or (b) of claim 1.

### Claim 3 (depends on 1)

An isolated nucleic acid molecule of claim 1 comprising a polynucleotide which encodes an epitope-bearing portion of a polypeptide in (a) of claim 1.

### Claim 4 (depends on 3)

The isolated nucleic acid molecule of claim 3, wherein said epitope-bearing portion of a polypeptide comprises an amino acid sequence listed in Table 4.

### Claim 5 (depends on 1)

A method for making a recombinant vector comprising inserting an isolated nucleic acid molecule of claim 1 into a vector.

### Claim 6 (depends on 5)

A recombinant vector produced by the method of claim 5.

### Claim 7 (depends on 6)

A host cell comprising the vector of claim 6.

### Claim 8 (depends on 7)

A method of producing a polypeptide comprising:
(a) growing the host cell of claim 7 such that the protein is expressed by the cell; and
(b) recovering the expressed polypeptide.

### Claim 9

An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:
(a) a complete amino acid sequences of Table 1;
(b) a complete amino acid sequence of Table 1 except the N-terminal residue;
(c) a fragment of a polypeptide of Table 1 having biological activity; and
(d) a fragment of a polypeptide of Table 1 which binds to an antibody specific for a S. aureus polypeptide.

### Claim 10

An isolated polypeptide comprising an amino acid sequence at least 95% identical to an amino acid sequence of Table 1.

### Claim 11

An isolated epitope-bearing polypeptide comprising an amino acid sequence of Table 4.

### Claim 12 (depends on 9)

An isolated antibody specific for the polypeptide of claim 9.

### Claim 13 (depends on 12)

A host cell which produces an antibody of claim 12.

### Claim 14 (depends on 9)

A vaccine, comprising:
(1) one or more S. aureus polypeptides selected from the group consisting of a polypeptide of claim 9; and
(2) a pharmaceutically acceptable diluent, carrier, or excipient;
wherein said polypeptide is present, in an amount effective to elicit protective antibodies in an animal to a member of the Staphylococcus genus.

### Claim 15 (depends on 9)

A method of preventing or attenuating an infection caused by a member of the Staphylococcus genus in an animal, comprising administering to said animal a polypeptide of claim 9, wherein said polypeptide is administered in an amount effective to prevent or attenuate said infection.

### Claim 16 (depends on 1)

A method of detecting Staphylococcus nucleic acids in a biological sample comprising:
(a) contacting the sample with one or more nucleic acids of claim 1, under conditions such that hybridization occurs, and
(b) detecting hybridization of said nucleic acids to the one or more Staphylococcus nucleic acid sequences present in the biological sample.

### Claim 17

A method of detecting Staphylococcus nucleic acids in a biological sample obtained from an animal, comprising:
(a) amplifying one or more Staphylococcus nucleic acid sequences in said sample using polymerase chain reaction, and
(b) detecting said amplified Staphylococcus nucleic acid.

### Claim 18 (depends on 9)

A kit for detecting Staphylococcus antibodies in a biological sample obtained from an animal, comprising
(a) a polypeptide of claim 9 attached to a solid support; and
(b) detecting means.

### Claim 19 (depends on 9)

A method of detecting Staphylococcus antibodies in a biological sample obtained from an animal, comprising
(a) contacting the sample with a polypeptide of claim 9; and
(b) detecting antibody-antigen complexes.

### Claim 20 (depends on 9)

A method of detecting a polypeptide of claim 9 comprising:
(a) obtaining a biological sample suspected of containing said polypeptide; and
(b) determining the presence or absence of said polypeptide in said biological sample.

### Claim 21 (depends on 20)

The method of claim 20, wherein said method comprises a step of contacting the sample with an antibody.
